GlassScriptPhysician profile
Susan A Gingrich
NPI 1841371002
$1,198.77
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $284 · 2023: $531 · 2024: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $228.97 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $213.33 | 2023-2024 | Imfinzi |
| Amgen INC. | $187.72 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2023 | Tazverik |
| Sobi, INC | $83.82 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $68.95 | 2023 | Reblozyl |
| Abbvie INC. | $51.17 | 2023-2024 | |
| Beigene USA, INC. | $31.01 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $29.26 | 2024 | Enhertu |
| Genzyme Corporation | $29.03 | 2023 | |
| Eisai INC. | $23.78 | 2023 | |
| Mirati Therapeutics, INC. | $23.52 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $23.37 | 2023 | Tavalisse, Rezlidhia |
| Novartis Pharmaceuticals Corporation | $21.65 | 2024 | |
| Seagen INC. | $19.90 | 2023 | Adcetris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2019 | |
| Taiho Oncology, INC. | $18.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Gingrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.